Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients

Amyotrophic Lateral Sclerosis

Volumn 13, Issue 4, 2012, Pages 357-362

  Ignjatović, Aleksandar ^a   Stević, Zorica ^b   Lavrnić, Dragana ^b   Nikolić Kokić, Aleksandra ^a   Blagojević, Duško ^a   Spasić, Mihajlo ^a   Spasojević, Ivan ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Iron; Ligands; Oxidative stress

Indexed keywords

IRON CHELATE; MANGANESE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRON SPIN RESONANCE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; CEREBROSPINAL FLUID; ELECTRON SPIN RESONANCE SPECTROSCOPY; FEMALE; HUMANS; HYDROXYL RADICAL; IRON; LIGANDS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84861640240     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2012.665929     Document Type: Article

References (46)

1. Strong M, Rosenfi eld J. Amyotrophic lateral sclerosis. A review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:136-143.
2. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 2005;5:77-87.
3. Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: Benefi cial or detrimental effects? J Neurol Sci. 2000;180:7-14.
4. Shaw PJ, Ince PG. Glutamate excitotoxicity and amyotrophic lateral sclerosis. J Neurol. 1997;244:S3 - 14.
5. Bolanos JP, Moro MA, Lizasoain I, Almeida A. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. Adv Drug Deliv Rev. 2009;61:1299-1315.
6. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Remarkable increase in cerebrospinal fluid 3 - Nytrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129-131.
7. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett. 1999;260:204-206.
8. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064-2074.
9. Ilieva EV, Ayala V, Jove M, DalfóE, Cacabelos D, Povedano M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130:3111-3123.
10. Nakagomi S, Barsoum MJ, Bossy-Wetzel E, Sütterlin C, Malhotra V, Lipton SA. A Golgi fragmentation pathway in neurodegeneration. Neurobiol Dis. 2008;29:221-231.
11. Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998;44:696-699.
12. M orimoto S, Kuzuhara S, Kokubo Y. Increased oxidative stress in patients with amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii peninsula, Japan. Mov Disord. 2009;24:123-126.
13. Spasojević I, Stević Z, Nikolić -Kokić A, Jones DR, Blagojević D, Spasić MB. Different roles of radical scavengers: Ascorbate and urate in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep. 2010; 15:81-6.
14. Spasojević I, Mojović M, Stević Z, Spasić SD, Jones DR, Morina A, et al. Bioavailability and catalytic properties of copper and iron for Fenton chemistry in human cerebrospinal fl uid. Redox Rep. 2010;15:29-35.
15. Halliwell B, Gutteridge JMC, editors. Free Radicals in Biology and Medicine. Oxford: Oxford University Press; 2007.
16. Liu D, Wen J, Liu J, Li L. The roles of free radicals in amyotrophic lateral sclerosis: Reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999;13:2318-2328.
17. Lenter C, editor. Geigy Scientifi c Tables. Caldwell: West Ciba-Geigy, 1981.
18. Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993; 189:843-846.
19. Cheung G, Gawal MJ, Cooper PW, Farb RI, Ang LC, Gawal MJ. Amyotrophic lateral sclerosis: Correlation of clinical and MR imaging fi ndings. Radiology. 1995;194: 263-70.
20. Hecht MJ, Fellner F, Fellner C, Hilz MJ, Neundör fer B, Heuss D. Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: A follow-up examination including FLAIR images. J Neurol Sci. 2002;199:59-65.
21. Santillo AF, Skoglund L, Lindau M, Eeg-Olofsson KE, Tovi M, Engler H, et al. Frontotemporal dementia-Amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Dis Assoc Disord. 2009;23:298-300.
22. Yasui M, Ota K, Garruto RM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and Parkinsonism-dementia. Neurotoxicology. 1993;14:445-450.
23. Nikolić Kokić A, Stević Z, Stojanović S, Blagojević DP, Jones DR, Pavlović S, et al. Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep. 2005;10:265-270.
24. Kell DB. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive infl ammatory and degenerative diseases. BMC Med Genomics. 2009;2:2.
25. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson 's, Huntington 's, Alzheimer 's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010;84:825-889.
26. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994;124:94-107.
27. Spasojević I. Free radicals and antioxidants at a glance using EPR spectroscopy. Crit Rev Clin Lab Sci. 2011;48: 114-42.
28. Mat í as-Guiu J, Galán L, Garcí a-Ramos R, Barcia JA, Guerrero A. Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis. Neurolog í a. 2010;25:364-373.
29. Drechsel H, Jung G. Peptide siderophores. J Pept Sci. 1998;4:147-181.
30. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51:333-355.
31. Bonnet AM, Tell G, Schechter PJ, Grove J, Saint-Hilaire MH, De Smet Y, et al. Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. Mov Disord. 1987;2:117-123.
32. Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord. 2009;24:1411-1426.
33. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates regionspecifi c accumulation. J Neurosci. 1998;18:8126-8132.
34. Il zecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 2003;107:412-418.
35. Kaufmann E, Boehm BO, Süssmuth SD, Kientsch-Engel R, Sperfeld A, Ludolph AC, et al. The advanced glycation endproduct N epsilon-(carboxymethyl) lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2004;371:226-229.
36. Yoshida Y, Une F, Utatsu Y, Nomoto M, Furukawa Y, Maruyama Y, et al. Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Intern Med. 1999;38:133-139.
37. Museth AK, Brorsson AC, Lundqvist M, Tibell LA, Jonsson BH. The ALS associated mutation G93A in human copperzinc superoxide dismutation selectively destabilizes the remote metal binding region. Biochemistry. 2009;48: 8817-29.
38. Tumani H, Teunissen C, Süssmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diag. 2008;8:479-494.
39. Ekegren T, Hanrieder J, Bergquist J. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: Exemplifi ed in amyotrophic lateral sclerosis biomarker discovery research. J Mass Spectrom. 2008;43: 559-71.
40. Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, et al. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 2011; 8:310-321.
41. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2009;23:3766-3779.
42. Bajić A, Zakrzewska J, Godjevac D, Andjus P, Jones DR, Spasić M, et al. Relevance of the ability of fructose 1, 6-bis(phosphate) to sequester ferrous but not ferric ions. Carbohydr Res. 2011;346:416-420.
43. Menéndez-Gonzál ez M, Pérez-Piñera P, Martí nez-Rivera M, Muñiz AL, Vega JA. Immunotherapy for Alzheimer's disease: Rational basis in ongoing clinical trials. Curr Pharm Des. 2011;17:508-520.
44. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457-67.
45. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011; 118:658-667.
46. Hasegawa T, Mikoda N, Kitazawa M, LaFerla FM. Treatment of Alzheimer's disease with anti-homocysteic acid antibody in 3xTg-AD male mice. PLoS One. 2010;5:e8593.